Introduction Canine hemangiosarcoma shows high metastatic potential and short OS. The gold standard consists of surgery followed by doxorubicin-based chemotherapy. In this prospective study, we compared adjuvant doxorubicin-cyclophosphamide (AC) with doxorubicin-dacarbazine (ADTIC) chemotherapy to determine safety and efficacy. Methods Dogs with histologically-confirmed, surgically-removed and completely staged hemangiosarcoma were enrolled. Tumour characteristic, chemotherapy protocol, toxicity, TTM and OS were analyzed. Dogs were divided in Group 1 (AC) and in Group 2 (ADTIC). Results Sixteen dogs with biologically aggressive hemangiosarcoma were enrolled; 9 received AC (Group 1) and 7 had ADTIC (Group 2). In Group1, 2 dogs had BM toxicity (grade 1 and 3) and 4 had GI toxicity (grade 1-3). In Group 2, 5 dogs had BM toxicity (grade 2-4) and 2 had GI toxicity (grade 1-2). In Group 1, 8/ 9 dogs developed metastases; TTM was 90 days. In Group 2, 4/7 dogs developed metastases; TTM was 365 days. TTM increased in ADTIC group (p=0.094). In Group 1, 9/9 dogs died, 7 due to hemangiosarcoma; the mean OS was 90 days. In Group 2, 4/7 dogs died due to hemangiosarcoma and 3 dogs were alive at 450, 465 and 585 days. Group 2 showed a longer mean OS (P=0.066). Conclusions ADTIC group had a positive trend for TTM and OS compared with AC group. Cyclophosphamide and dacarbazine are both alkylating agents; however, dacarbazine shows increased fractional dose intensity, resulting in higher summation dose intensity of ADTIC compared with AC. Furthermore, ADTIC was well tolerated requiring no dose reductions.
PRELIMINARY STUDY ON A COMBINED DOXORUBICIN-DACARBAZINE CHEMOTHERAPEUTIC PROTOCOL FOR THE ADJUVANT TREATMENT OF CANINE HEMANGIOSARCOMA / Finotello R.; Marchetti V.; Stefanello D.; Bettini G.; Poli A.; Beatrice L.; Marconato L. - STAMPA. - (2012), pp. 15-15. (Intervento presentato al convegno 2nd World Veterinary Cancer Congress tenutosi a Paris nel 1-3 March, 2012).
PRELIMINARY STUDY ON A COMBINED DOXORUBICIN-DACARBAZINE CHEMOTHERAPEUTIC PROTOCOL FOR THE ADJUVANT TREATMENT OF CANINE HEMANGIOSARCOMA
BETTINI, GIULIANO;Marconato L.
2012
Abstract
Introduction Canine hemangiosarcoma shows high metastatic potential and short OS. The gold standard consists of surgery followed by doxorubicin-based chemotherapy. In this prospective study, we compared adjuvant doxorubicin-cyclophosphamide (AC) with doxorubicin-dacarbazine (ADTIC) chemotherapy to determine safety and efficacy. Methods Dogs with histologically-confirmed, surgically-removed and completely staged hemangiosarcoma were enrolled. Tumour characteristic, chemotherapy protocol, toxicity, TTM and OS were analyzed. Dogs were divided in Group 1 (AC) and in Group 2 (ADTIC). Results Sixteen dogs with biologically aggressive hemangiosarcoma were enrolled; 9 received AC (Group 1) and 7 had ADTIC (Group 2). In Group1, 2 dogs had BM toxicity (grade 1 and 3) and 4 had GI toxicity (grade 1-3). In Group 2, 5 dogs had BM toxicity (grade 2-4) and 2 had GI toxicity (grade 1-2). In Group 1, 8/ 9 dogs developed metastases; TTM was 90 days. In Group 2, 4/7 dogs developed metastases; TTM was 365 days. TTM increased in ADTIC group (p=0.094). In Group 1, 9/9 dogs died, 7 due to hemangiosarcoma; the mean OS was 90 days. In Group 2, 4/7 dogs died due to hemangiosarcoma and 3 dogs were alive at 450, 465 and 585 days. Group 2 showed a longer mean OS (P=0.066). Conclusions ADTIC group had a positive trend for TTM and OS compared with AC group. Cyclophosphamide and dacarbazine are both alkylating agents; however, dacarbazine shows increased fractional dose intensity, resulting in higher summation dose intensity of ADTIC compared with AC. Furthermore, ADTIC was well tolerated requiring no dose reductions.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
